BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aptus Endosystems Inc. Completes $25 Million Series BB Financing


6/27/2012 9:13:11 AM

SUNNYVALE, Calif.--(BUSINESS WIRE)--Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced closing on $25 million of equity financing. Synergy Life Science Partners, a new investor, led the round and was joined by existing investors US Venture Partners and Longitude Capital Management. Mudit K. Jain, Ph.D., Partner at Synergy Life Science Partners will join the company’s Board of Directors.

Proceeds from the financing will be used to expand commercialization of the HeliFX™ Aortic Securement System in the United States and Europe, where the company has already obtained US Food and Drug Administration (FDA) clearance and CE Mark, respectively. In addition, Aptus will develop further HeliFX product offerings to fulfill unmet needs in the treatment of aortic aneurysms and thus increase the patient population who could benefit from HeliFX. The company also plans to execute a US clinical trial of the Fortevo™ AAA Endograft System in support of filing for Premarket Approval with the FDA. Lastly, Aptus will expand utilization of the Fortevo system in key European centers, where it already possesses the CE Mark.

“This commitment on the part of Synergy Life Sciences Partners and our current investors provides the company with necessary capital required to bring the HeliFX and Fortevo family of products to physicians treating patients with life threatening aortic aneurysms,” said James Reinstein, President and CEO of Aptus Endosystems. “We will judiciously utilize these funds to expand the use of HeliFX in targeted markets and introduce new aortic repair products, all while approaching profitability.”

“Aptus’ HeliFX and Fortevo technology platforms provide an innovative treatment option for millions of patients suffering from AAA,” said Mr. Jain. “We believe that Aptus’ proprietary technology and world class management team uniquely position the company for significant growth in years ahead.” Alan Kaganov, Sc. D, Partner at US Venture Partners and Chairman of the Aptus Board added that “USVP is very encouraged by the accomplishments of the Aptus team. We welcome Synergy Life Science Partners to Aptus and collectively, we will continue to support the company’s endograft and fixation platforms to ensure that both patients and physicians have access to a new standard in long-term durability in EVAR.”

About Aptus Endosystems, Inc.

Headquartered in Sunnyvale, Calif., Aptus Endosystems is a privately held medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR). An estimated 1.5 million Americans have an abdominal aortic aneurysm (AAA), which can be life-threatening if left untreated and approximately 200,000 people are newly diagnosed each year. Aptus Endosystems has developed a unique endograft and innovative helical anchor technology that allows physicians to perform minimally invasive EVAR while still providing the control and potential long term durability of an open surgical repair. The FortevoTM AAA Endograft System and the HeliFXTM Aortic Securement System bear the CE Mark for distribution in the European Union. The HeliFX Aortic Securement System is cleared by the FDA for distribution in the United States. The Fortevo AAA Endograft System is Investigational Use Only in the United States. For more information, please visit www.aptusendosystems.com.

Contacts

Media Contact:

Aptus Endosystems, Inc.

James Reinstein, CEO

Ph: 408.530.9050

jreinstein@aptusendo.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES